Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EBT (2016 - 2025)

Rocket Pharmaceuticals' EBT history spans 10 years, with the latest figure at -$43.7 million for Q4 2025.

  • For Q4 2025, EBT rose 28.93% year-over-year to -$43.7 million; the TTM value through Dec 2025 reached -$230.4 million, up 13.64%, while the annual FY2025 figure was -$230.4 million, 13.64% up from the prior year.
  • EBT for Q4 2025 was -$43.7 million at Rocket Pharmaceuticals, up from -$52.0 million in the prior quarter.
  • Across five years, EBT topped out at -$33.8 million in Q2 2021 and bottomed at -$71.9 million in Q2 2024.
  • The 5-year median for EBT is -$61.2 million (2023), against an average of -$57.1 million.
  • The largest annual shift saw EBT crashed 71.22% in 2021 before it increased 28.93% in 2025.
  • A 5-year view of EBT shows it stood at -$43.9 million in 2021, then tumbled by 55.43% to -$68.3 million in 2022, then rose by 7.86% to -$62.9 million in 2023, then rose by 2.2% to -$61.6 million in 2024, then rose by 28.93% to -$43.7 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's EBT are -$43.7 million (Q4 2025), -$52.0 million (Q3 2025), and -$71.1 million (Q2 2025).